We are IntechOpen, the world’s leading publisher of Open Access books
Built by scientists, for scientists

5,100
Open access books available

126,000
International authors and editors

145M
Downloads

154
Countries delivered to

TOP 1%
Our authors are among the most cited scientists

12.2%
Contributors from top 500 universities

WEB OF SCIENCE™
Selection of our books indexed in the Book Citation Index in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?
Contact book.department@intechopen.com

Numbers displayed above are based on latest data collected.
For more information visit www.intechopen.com
Abstract

Lung cancer is one of the leading causes of cancer death among both men and women, making up almost 25% of all cancer deaths. Precision medicine shows promise for improving many aspects of health and healthcare, including tests, drugs, and other technologies that support innovation, with the possibility of new partnerships with scientists in a wide range of specialties. Non–small-cell lung cancer (NSCLC) has become a prominent example of the success of precision medicine in treating solid tumor malignancies. The first step in this process involves new blood-based diagnostics, which can now noninvasively provide clinically useful information. However, the identification of novel biomarkers that could be used in early diagnosis is urgently needed, especially for guiding initial therapy and predicting relapse or drug resistance following the administration of novel targeted therapies.

Keywords: precision medicine, target therapy, liquid biopsy, CTC, CSCs, miRNA, NGS, NSCLC

1. Lung cancer and the meaning of “precision medicine”

The scientific community tends to conflate the meanings of “precision medicine” and “personalized medicine” [1, 2]. In fact, the National Research Council defines “personalized medicine” with an old meaning quite similar to that of “precision medicine.” However, whereas personalized medicine mainly focuses on medical actions for a single person, precision medicine explores various factors affecting that person’s condition, such as diseases, the environment, etc. [3].

Precision medicine is able to provide specific genetic maps for patients with elevated cancer risks, potentially revealing gene mutations and thus calculating the likelihood of family members’ developing a certain type of cancer.

Recently, the use of precision medicine has been expanded to attempt treatment of several solid tumors, including those of breast, brain, and lung cancer [4, 5]. In general, the aim of precision medicine is to find the right treatment for a specific patient at the right dose and time, which is particularly important in cancer therapy.
Finding a precise treatment for a patient could eradicate the potential problem of the variability of treatment response, including resistance. In fact, one of the main problems with cancer treatments is a nonresponse to drug therapy and the consequent metastatization of the disease.

Precision medicine is being used to treat certain cancers to help discover what tests and treatments are best. In addition, doctors could employ precision medicine to identify those at high risk for cancer, to prevent certain types of cancer, for early cancer detection, to make specific cancer diagnoses, to select the best treatment options, and to evaluate treatment efficacy [6].

The history of focused therapies to combat lung cancer began with the approval of the small molecule tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) [7]. This marked the beginning of the era of targeted therapies for lung cancer. On a related note, in 2004 and 2007, the first discoveries of adenocarcinoma of the lung were identified as EGFR mutations and ALK-rearrangements. These new findings paved the way for new targeted therapies—namely, tyrosine kinase inhibitors (TKIs) [8]. The responses to these inhibitors and the subsequent discoveries from numerous clinical trials (NCT00322452, NCT00932893) [9, 10], led to incorporating them into daily clinical activities. This demonstrated that TKIs are more effective than traditional treatments, such as chemotherapy. In contrast, patients with non-EGFR mutant lung cancers do not respond to EGFR TKIs, and, for this reason, chemotherapy a more effective treatment for them [9]. To complicate cancer’s frequent resistance to chemotherapy, the related costs of targeted therapies, no drugs have been very effective in its treatment. Thus, the latter must be considered when introducing targeted therapies into clinical practice [11]. However, scientists have proceeded to define and characterize other oncogenic driver mutations in lung adenocarcinoma, such as KRAS. This mutation was first described in 1980 [12, 13], with a presence of 25–30% in lung adenocarcinoma and high aggression, which is even more dangerous without specific targeted therapies. Interestingly, the first recent study with promising clinical data came from a Phase I trial, in which the KRAS G12C inhibitor AMG 510 shrank lung cancer tumors harboring KRAS G12C mutations [14, 15]. This highlighted the importance of identifying new drivers’ mutations therapies in lung cancer for decreasing mortality and recurrence. Other mutations have been identified in lung cancer, including ERBB2 (3%), BRAF (2%), PIK3CA (1%), MAP2K1 (1%), and NRAS (1%), [16], although these are defined as niche mutations. Beyond the fact that these niche mutations are infrequent, they are no less dangerous, with a high level of mortality. On this subject, a recent study by Aramini et al. examined three cohorts of mutations selected from patients with lung adenocarcinoma [17]. These mutations were 1) BRAF, c-MET, DDR2, HER2, MAP2K1, NRAS, PIK3CA, and RET; 2) K-RAS; and 3) EGFR. In this pilot study, the researchers demonstrated that niche mutations exhibited an increased risk of death when compared with EGFR mutations and a similar risk of death when compared with KRAS mutations. This aspect is key in highlighting the importance of focusing attention not only on general mutations but also on niche mutations to develop more effective cures in larger populations. In fact, a clinical trial is currently being conducted to better define the less common oncogenic driver mutations (e.g., NCT01336634).

In lung adenocarcinoma patients, the importance of testing eventual genetic mutations introduced new diagnostic perspectives. These have enhanced the treatment recommendations of the International Association for the Study of Lung Cancer (IASLC) and National Comprehensive Cancer Network (NCCN) for patients with EGFR mutation and ALK positivity. Moreover, new mutations have been studied for diagnostic purposes, including ROS, RET, MET, BRAF, and HER2, although these
are infrequent mutations [18, 19, 20]. These studies have laid crucial groundwork for creating more focused treatments tailored to each patient [18, 19, 20].

Precise molecular tests led to the correlation of EGFR mutations and sensitivity to gefitinib and erlotinib in lung adenocarcinoma, especially in non-smokers or low-smokers. The EGFR tyrosine kinase inhibitors (TKIs) are considered the baseline treatment for this cancer, although a high percentage of patients develop resistance to therapy and experience a disease recurrence within nine months [18]. However, scientists discovered new mutations, developing a more focused panel of patients’ genetic characteristics. These researchers discovered that 50% of patients developing tumor dissemination showed a secondary EGFR mutation, such as T790M, which has been used for developing new target therapies, including AZD9291 and CO-1686 [21].

ALK, ROS, and RET, defined as receptor tyrosine kinase gene rearrangements, present at a frequency between 1 and 8% in lung adenocarcinoma, although patients harboring ALK fusion or ROS1 mutations have positively responded to crizotinib and to TKIs. However, these patients frequently develop recurrence, probably due to an acquired resistance and from mechanisms which must be further investigated [22, 23].

The target of mutations is particularly difficult, especially the study of the mitogen activation pathway (MAPK). This has been of recent interest for its implications regarding lung adenocarcinoma development and the subsequent results of therapeutics. Specifically, the MAPK activation mechanism has been found frequently along certain KRAS amino acids. Currently, KRAS is considered an aggressive mutation for its impact on overall survival (OS) in early-stage NSCLC. Finding specific RAS inhibitors may open the door to new target treatments that improve long-term survival and responses to therapies, even in patients with KRAS mutations. New treatments have been set against the downstream effectors of activated KRAS, such as MEK1/MEK2, PI3K, and AKT [24]. In addition, recent phase II data analyzing the inhibition of MEK1/MEK2 by selumetinib and docetaxel showed promising results in KRAS-muted patients [25].

Additional work on downstream effectors in the KRAS mutant pathway is crucial. Currently, several clinical trials employing the inhibition of PI3KCA, MEK, and PTEN are in progress [26].

Recently precision medicine is used not only in clinical practice to drive oncological decision but also in patients with rare tumors, likely due to their frequency in these patients’ family histories. This aspect is important for making medical decisions, as well as for screening.

The most frequent tests used at this time are biomarker tests, chromosome tests, gene tests, and biochemical tests, all of which are derived from blood, saliva, a tissue biopsy, or body fluids. These tests are named as follows: DNA mutational analysis, genomic testing, proteomics, biomarker testing, tumor profiling, cytogenetics, next generation sequencing, or molecular testing [27, 28].

1.1 NSCLC biomarkers

The use of drugs against NSCLC in locally advanced or advanced stages may help identify targeted drugs, which are more useful and better tolerated, as well as more responsive against lung cancer. The latter remains a serious problem in the world, accounting for over 1.7 million deaths in 2018 [29], showing that therapies are still largely ineffective. In particular, EGFR and ALK are considered biomarkers that predict positive responses to specific drugs. However, not all patients with lung cancer show these mutations, and this is why not all patients respond to gefitinib, erlotinib, or afatinib, which are currently considered the most effective against EGFR mutations [30, 31].
In addition, the ALK-positive gene is rare, occurring in approximately 5% of patients with NSCLC and eliciting production of a growth-promoting enzyme [32]. Patients who are ALK-positive are usually treated with crizotinib, a tyrosine kinase inhibitor that blocks the input of the growth signals to the nucleus of the cancer cell. Immunotherapy is the last defense against cancer, and it has been developed in the last decades, including cancer vaccines, oncolytic viruses, and administration of antibodies or recombinant proteins that co-stimulate or block the immune checkpoint pathways [33]. However, there is a pressing need to identify new targets specific to a larger cohort of patients with better outcomes than those of current chemotherapeutic treatments. This need has induced the scientific community to deeply analyze other mechanisms or approaches.

Although targeted drugs and chemotherapeutic agents may be useful for weeks or months against tumors in terms of disease control, the majority of tumor relapses occur after several months of treatment.

1.2 A new kind of drug treatment: Immune checkpoint inhibitors

A new class of drugs was recently developed by Allison et al. and named checkpoint inhibitors [34, 35]. This group has the specific role of enhancing patients’ immunity, thus increasing their chances of fighting cancer. The first one created was nivolumab, followed by pembrolizumab, which targets a receptor called programmed cell death-1 (PD-1).

However, not all patients have shown high levels of PD-1 expression in their cancer cells, revealing the major limitation of these therapies. In fact, the prognostic role of PD-L1 in solid tumors such as lung cancer, melanoma, etc. is still debated [36]. In patients with an overexpression of PD-L1, the use of antibodies able to target PD-1 and PD-L1 is one of the main points to consider for the setting of more effective therapies [37]. However, for the low immunohistochemistry accuracy based on PD-L1, the use of this biomarker as a possible predictor for satisfying immunotherapeutic results against cancer is under examination [38]. The main shortfalls of this marker are, first, the different cut-off values of positivity in different solid tumors; second, the sensitivity, which is very variable as demonstrated in several studies; and third, the potential involvement and impact of the tumor microenvironment associated with the use of other genes markers which, combined together, may be more helpful for a better-focused PD-1/PD-L1 blocking immunotherapy [39].

In particular, pembrolizumab—a humanized antibody used in cancer immunotherapy as a programmed cell death 1 (PD-1) inhibitor—seems to improve survival significantly more than standard chemotherapy in NSCLC patients with an expression of PD-1 ligand ≥50% in cancer cells [40, 41]. In addition, in nonsquamous NSCLC patients the PD-L1 positively expression of at least 1% represents a good responder against antitumor action. This aspect highlighted the importance of the presence of at least 1% PD-L1 expression for the treatment of NSCLC patients, which seem to represent two-thirds of all NSCLC population [42, 43]. In contrast, for small cell lung cancer (SCLC) which represents 15% of all types of lung cancers, there are actually few choices of cancer treatments and no molecularly targeted drug has been approved. In particular, the potential role of PD-1/PD-L1 inhibitors in SCLC has not been yet considered [44]. Recently, the first study analyzing the PD-L1 expression in SCLC has been conducted at Kyoto University Hospital, where the researchers analyzed the immunohistochemical expression of this marker in paraffin blocks from 39 patients affected by SCLC [45]. Although previous studies have been conducted—most likely for the use of different types of antibodies—the expression was arbitrary, and this represented an impediment in the elucidation of the possible
expression and role of PD-L1 in SCLC [46]. For the first time, the team from Kyoto University thought to use the standard PD-L1 antibody already tested in NSCLC with the same cut-off level (1%) as in NSCLC [45]. This approach was important to elucidate the presence of this marker, even in SCLC, although the correlation with the clinical aspects has not been yet defined.

In summary, all the aspects described would suggest that the use of PD-L1 as an exclusive biomarker in cancer may not represent a completely satisfying choice in terms of accuracy and efficacy. On the other side, at the moment, scientists cannot ignore the good responses against cancer that patients with at least 1% of positivity for PD-L1 show through the most-used checkpoint inhibitors [47]. In summary, further studies set on the combination among PD-1/PD-L1 pathways, the tumor microenvironment and other genes markers may open the way for new discoveries that are tailored to the individual patient and more effective against cancer.

2. Precision medicine and solid tumors

The development of new techniques and approaches to discovering signaling pathways to better understand tumor growth has opened to precision medicine for solid tumors [48].

In particular, the major field is to create future treatments tailored to each patient to improve their results against cancer. However, this aspect has not yet been focalized for the numerous difficulties related to the new cancer cells targets. Through current clinical trials, pharmaceutical companies are developing studies based on specific markers to find multiple options for the best treatment [49].

Recent advances regarding the biology behind these tumors have shown promising results. In several centers, patients are analyzed by RNA expression testing and protein analyses [50, 51]. These genetic analyses have already been taken into consideration, especially for hereditary tumors. Certain companies, such as Myriad Genetics Inc., have developed in the last decades several molecular diagnostic kits to test patients at risk of developing hereditary tumors [52, 53, 54]. Thus far, this aspect has been extensively analyzed for prostate cancer and breast cancer [55, 56]. It has been examined for the genes mutations that are more frequent in these diseases, as well as the development of prognostic scores related to cancer recurrence [57].

At the moment, the possibility of developing a molecular profile is limited for the presence of mutations and other genetic variations. However, scientists are planning to develop a molecular profile based on RNA expression, as described for familiar genetic diseases or by immunity profiles. There is an urgent need to develop new approaches and targeted treatments to better stratify cancer patients, to prevent recurrence, and to more effectively treat these patients.

Several clinical trials are running regarding the possibility of targeting oncologic patients. Some of these trials involve specific tumors, such as BATTLE I and II [58], and some are non-tumor specific. These studies have been designed as observational, randomized, and non-randomized [59–62].

Non-randomized trials are studying molecular profiles in the Clinical Laboratory Improvement Amendments (CLIA) certified laboratories, which were founded in 2013 in collaboration with pharmaceutical societies to identify a specific genes patent for each patient. In particular, pharmaceutical companies have been conducting independent trials of drugs in patients with specific genetic profiles [63].

However, these profiles may not be the same for patients with several solid tumors, but at this time, this aspect is not well known. The National Cancer
Institute (NCI) is preparing a study with the involvement of agents from different companies [64]. The baseline for these studies, called NCI-MATCH studies, will be the analysis by a consortium of NCI-selected CLIA-certified laboratories of the genomic profiles of several cancer patients. This process will use a new approach called next generation sequencing (NGS) for a number of selected genes.

Another interesting study, the SHIVA study, randomizes patients with specific genetic abnormalities matching generic types of cancer and patients’ specific genes. It examines the possible results from standard treatments in terms of cytotoxicity and disease progression [65].

These types of combined studies involving several companies and certified laboratories may be very important to further discoveries, but the difficulty of coordinating multiple companies constitutes an effective impediment. Basic research is suggested to more deeply analyze the mechanisms and mutations involved in development and tumor progression [66, 67]. A representative panel during time of the major achievements for lung cancer therapy (Figure 1).

Regarding the mutations, those in the scientific community do not believe that studying a single mutation or a small panel of genes would be enough to influence future decisions or treatments for oncological patients. For this reason, the new advanced technologies require a larger panel of genes or intra- and inter-tumor heterogeneity at the protein, genetic, and epigenetic levels [68, 69]. Specifically, the genetic analysis of RNA and proteins in primary or metastatic diseases in patients with renal carcinomas have shown a large heterogeneity of cells and genes inside the tumors. This is one of the main obstacles in the battle against cancer [68, 69]. On the other hand, in colorectal and lung cancer, the panel of genes that seem to be involved is limited [70, 71]. One must be considered, such as in the case of lung cancer. Such a tumor could develop several mutations during its progression, and these would be persistent in evolving. For this reason, future patients’ tumor profiles would need to be frequently updated to guarantee the best treatment options. One problem would be the impossibility of obtaining sufficient material from
biopsies. In addition, it would be difficult to ask these patients to perform several biopsies in order to have a more focused treatment. Thus, in order to minimize invasive procedures, scientists have attempted to develop the best approach with the least aggressiveness toward the patient. For example, the analysis of circulating free DNA (cfDNA) by liquid biopsy, widely discussed at this time, and CTCs may be considered of great value if these approaches are able to replace multiple biopsies. For the moment, the results of these techniques seem to be promising, but further investigation is needed regarding each type of solid tumor, as well as each patient [72, 73, 74].

Even the serum proteins are of interest; however, the difficulty in identifying a specific protein has made this approach very difficult to use for tumor patients. For example, PSA levels for prostate cancer patients, as well as CEA measurements, are commonly used markers, but several clinical trials and basic research are necessary to identify more markers for future cancer diagnoses [75–77].

In summary, important progress has been made in terms of molecular profiles and developing advanced genetic technologies. However, the coming years will be crucial in determining whether these new aspects will revolutionize treatments and improve prognoses in cancer patients.

3. Recent discoveries in precision-diagnostic and precision-therapeutic approaches to lung cancer

New genetic discoveries through high-throughput techniques could allow the establishment of a new era in which precision medicine could be routinely used for cancer treatment, as well as in its diagnosis and therapy [78]. Since the early 2000s, innovative sequencing systems called next-generation sequencing methods (NGS, Next Generation Sequencing), or massive parallel sequencing (MPS, Massive Parallel Sequencing), have been used to define high-efficiency nucleotide sequences in the simultaneous, independent analysis of millions of bp of DNA. In particular, the association of genomic data and the identification of new biomarkers may modify cancer treatments in the near future. This would require extensive knowledge of the mutational analysis of a panel of cancer genes, along with determination of copy-number variations and any other structural rearrangements. As with lung cancer, which has a high rate of recurrence after surgery independent from stages, it would be useful in treating other solid tumors to have some predictor of relapse based on genetic tests identifying the individual risks of various cancers and their consequent relapses. This chapter will discuss technical considerations for developing genomic precision diagnostic tools for clinicians to support their further use in oncological care and research trials, as represented schematically in Figure 2.

3.1 Single-gene assays versus next-generation sequencing

Until now, the most commonly used methods have included DNA or RNA amplification using polymerase chain reaction (PCR), followed by classical Sanger sequencing or pyrosequencing, analysis of fragments by electrophoresis after digestion with restriction enzymes, or fluorescent in situ hybridization with specific probes (FISH) [79]. Single gene analysis often has significant advantages over large-scale genomic sequencing due to the lower cost and reduced complexity in test development, execution, and interpretation. In molecular oncology, for example, there is frequent identification of BCR-ABL1 translocation by FISH in patients with chronic myeloid leukemia. Single gene analysis is a useful approach when the genetic alterations are well known. On the other hand, high-throughput screening,
such as NGS, is more sensitive than many monogenic methodologies, such as Sanger sequencing. As a consequence of the discovery of more relevant genes in a clinical context, NGS has become an increasingly attractive approach. Molecular testing of advanced non-small cell lung cancer (NSCLC) provides a good example of the rapidly growing need for the molecular profile of several genes, especially cancer. Initially, the only knowledge about the genetics of lung cancer was the deletion of exon19 in the EGFR gene and the mutation of the L858R gene, which could lead to the first targeted therapy with tyrosine kinase inhibitor (TKI) [80–88]. However, within a few years, effective targeted therapies approved by the U.S. Food and Drug Administration (FDA) have been developed and are now effective in treating lung cancer with other EGFR and BRAF mutations [83, 84], as well as ALK and ROS1 rearrangements [84–88]. Other solid tumors have been associated with target therapies involving other molecular alterations, such as exon 14 MET skip mutations [89–91], RET rearrangements [92–94], and ERBB2 (HER2) mutations [95], which have led to a new setting for therapeutic recommendations from the National Comprehensive Cancer Network (NCCN) [96].

3.2 Gene panels versus unbiased genomic and transcriptomic analyses

Given their high speed of execution, NGS techniques have been used for the identification of disease genes by whole genome sequencing (WGS) or whole exome sequencing (WES), as well as target gene panels [97]. The potential advantage of these techniques is the possibility of detecting essentially any genomic alteration, including novel or rare alterations. However, certain critical points must be considered. To begin, WGS is far too expensive and generates a huge amount of raw data requiring complex bioinformatics analyses to extract useful information. As a consequence, analysis may be performed only on selected cases. In NSCLC, for instance, whole-genome studies have demonstrated a median of 888 and 15,659 mutations.
in NSCLC samples from, respectively, nonsmokers and smokers [98]. The major part of these variants lacks any relevant pathogenic significance. Nevertheless, the comparison between tumor and normal DNA is mandatory, distinguishing somatic mutations, due to cancer, from germline polymorphisms, which will be inherited by patients’ offspring. However, WES is an unbiased approach that has also found utility in certain laboratories as a tool for unraveling cancers. WES limits sequencing to the ~1.5% of the genome that lies in the exons of genes. Nevertheless, this approach also generates a large number of potential variants, the vast majority of which even in this case currently do not have annotated clinical implications. Exome sequencing would also fail to detect pathogenic variants, such as structural rearrangements with intronic breakpoints. DNA quality requirements are lower than those of WGS, so the drawbacks of this approach include the fact that the depth of sequencing obtained through WES is much lower than that obtained from targeted panels. For diagnostic purposes, it has been argued that a high sensitivity is needed to reduce the number of false negatives. Although a genetic variant of uncertain significance can be detected, it would be better to be cautious even if there were no clinical treatment for the alteration. Another crucial element that may be investigated with WGS is the copy number alteration (CNA), which is a parameter that takes into account the number of repeated alterations in the DNA. These hallmarks in cancer often lead to the activation of oncogenes and inactivation of tumor suppressor [99].

The WES is primarily used to discover all of the variations in the DNA sequence, but the RNA-Seq is specifically used for the measurement of gene expression, gene fusion detection, and identification of splicing events, since it is based on direct sequencing of cDNA. One of the most important applications of the RNA-Seq is for cancer. For example, a large-scale RNA-Seq has been useful for the detection of several cancer driver genes in adenocarcinoma of the lungs [100, 101]. That study compared the transcriptome of lung cancers between smokers and nonsmokers and found a significant difference in the number of point mutations between the two groups. In summary, the amount of smoking (packs/year) was positively correlated with the number of somatic point mutations in the cancer genome. As for the study described, a complete molecular analysis conducted on the transcriptome or the entire genome or exosome through higher coverage of the genomic regions allowed the detection of lower-level molecular alterations. Moreover, the principle difference between targeted genetic panels and unbiased, extensive genomic and transcriptomic analysis is not necessary in the last case to know a priori the molecular alterations to be detected.

3.3 Applications of molecular oncology

3.3.1 Diagnosis

For different tumors, molecular diagnostic tests, as for example, BCR-ABL1 in chronic myeloid leukemia or other data, may be very helpful in influencing the decisions of oncologists or pathologists. That is, they could develop more detailed diagnoses, as well as more appropriate approaches, although molecular analyses would need to be correlated with clinicopathological patients’ characteristics.

In particular, certain mutations detected in malignant tumors have also been found in healthy individuals [102, 103, 104]. However, the new technologies related to advanced molecular analysis are now able to distinguish between cancer mutations and normal tissue mutations. One of the most important aspects of this precision medicine tailored to the patient is the possibility of stratifying the prognosis. Several studies are examining this aspect in several solid tumors [105–108].
3.3.2 Therapy

Several clinical trials are currently being conducted regarding specific target alterations in different cancer types. The Molecular Analysis for Therapy Choice (MATCH; http://www.cancer.gov/aboutcancer/treatment/clinical-trials/nci-supported/nci-match) trial and the Targeted Agent and Profiling Utilization Registry (TAPUR) trial were designed to identify particular molecular targets able to determine a specific therapy against cancer. The main difficulty arises from the fact that each tumor shows a specific mutation that may be different in each patient. This genetic heterogeneity has led to targeting specific drivers in each tumor. Furthermore, the identification through the NGS technique introduced new possibilities for finding specific oncogenic drivers that could maximize the possibility of receiving the benefit of a very focused, tailored therapy. The use of NGS is intended to guide treatment decisions. In fact, this technique can identify oncogenic alterations, which may be target inhibitors or monoclonal antibodies. For example, the BRAF V600E mutation can be cured by BRAF inhibitors and MEK inhibitors approved by the FDA. For instance, patients with colorectal cancer and KRAS and NRAS mutations showed a therapeutic resistance to EGFR antibody therapy [109, 110].

The integration of genomic results into reports and the clinical decision supported by NGS are a powerful tool that enables the simultaneous interrogation of many regions of the human genome [111]. However, as the volume of data from NGS testing grows, so does the challenge of distinguishing the findings that are clinically meaningful and prioritizing their clinical utility. Given the large number of genetic variants that occur in cancer genomes and the many low-frequency or nonrecurring mutations detected using NGS, a systematic approach to prioritizing variants is necessary to effectively implement NGS-based precision diagnostics in routine clinical contexts [112]. Molecular pathologists, in collaboration with their oncology colleagues, have been tasked with evaluating this abundance of data, distilling it to what is clinically relevant, and communicating this information in the most cogent, manageable manner possible. Several components are required to properly integrate genomic results into clinical reports, among which is the understanding of the clinical evolution of the genomic variant in patients.

4. Future perspectives on lung cancer treatments

The role of cfDNA has been extensively analyzed in terms of the definition of new-targeted therapies, and the interpretation of this role in driving immunotherapy has just begun [113]. The mutation in a cancer patient can be studied from cfDNA by NGS [114]. Only one study has found conflicting results from the blood tumor mutation burden (TMB) [115]. It has been found that a high blood sample, TMB, is correlated with the reaction to inhibitors of programmed cell death (PD)1 and its ligand (PD-L1) [115, 116], as in NSCLC with atezolizumab in POPLAR and OAK trials [117]. The TMB is more correlated with advanced disease, and it expresses a high value of circulating tumor DNA (ctDNA) concentrations [118]. Different studies have shown that there is a correlation between ctDNA kinetics and clinical course in terms of possibility of predicting the prognosis [119]. In particular, it has been demonstrated that the variation of circulating the tumor DNA burden is able to distinguish a real and unreal tumor progression. Another interesting application of cfDNA, which scientists are studying, is the possibility of detecting the minimal residual disease (MRD) for the setting of immunotherapy or the...
possibility of finding the drug resistance as JAK1/2 or B2M mutations [120]. With regard to the early stages’ NSCLC, the prospect of setting screening tests is very challenging. The National Lung Screening Trial [121] and the NELSON trial have shown that to test asymptomatic men with high risks factors by chest CT reduced the deaths in men to 26% and in women to 41% [122]. However, the problem of false positives is still one of the most difficult factors to eliminate [123]. These trials showed that the combination of the high sensitivity of CT scans and liquid biopsy may have an important effect in driving clinical decisions, as well as therapeutic approaches. One limitation is the fact that ctDNA quantities may be low or absent in the early stages of disease [124]. Another important value of cfDNA assay may be the opportunity to identify recurrent mutations. This aspect is important in terms of prognosis and developing new targeted treatments. For example, the Cancer SEEK assay can combine the genomic analysis of 16 genes in ctDNA and eight biomarkers detectable for eight non metastatic diseases [125–127]. Nevertheless, certain limitations remain regarding sensitivity to early-stage detection. For instance, lung cancer does not currently have a specific circulating protein marker. The most promising test at the moment is the multi-region exome sequencing of a tumor, but this technique is limited by the costs and the excessive time required, which make this approach currently unavailable to the patients. However, the most discussed approaches developed for circulating tumor cells (CTC) isolation are based on the following: 1) antigen expression and 2) biophysical characteristics [128–130].

In summary, the microfluidic technologies have probably been the most common approach to CTC isolation since 2007, with the “CTC-ship” [131]. However, several limitations are ongoing, and further studies must better stratify this approach not only in the early stages of NSCLC but also for other solid tumors. The world of exosomes is complex because of their vast numbers and various roles. In particular, they were found to contain microRNA (miRNA) that could be exchanged via horizontal intercellular transfer with the possibility of activating an oncogene or a tumor suppressor gene. In 60–75% NSCLC, miRNAs play crucial roles. Moreover, recent studies have provided evidence that exosomes may mediate interactions among different types of cells to enhance cell–cell communication within the tumor microenvironment. In particular, exosome signaling may provide new insights into how cancer stem cells (CSCs) confer drug resistance between drug-resistant and drug-sensitive cells [132]. In fact, CSCs exhibit self-renewal, proliferation, tumor initiation, and propagation, and the “stemness” of cancer cells seems to be supported by the release of exosomes [133, 134, 135]. Cancer stem cells are thought to secrete microvesicles and exosomes that interact with neighboring stromal cells. For instance, experimental evidence has shown that breast cancer stem cells secrete exosomes with characteristics of cancer cell-derived exosomes [135, 136]. Exosomes released by cancer stem cells mediate tumor growth in different cancer types. For example, in a renal cancer model, microvesicles released from human renal cancer stem cells were described to stimulate angiogenesis and the formation of a pre-metastatic niche in the lungs [137]. Elsewhere, a study on glioma stem cells reported that glioma-associated stem cells increased the biological aggressiveness of glioma-initiating cells through the release of exosomes. However, both exosomes and cancer stem cells targeted against tumors must be thoroughly analyzed in the future. This is important because there is no clear identification of a specific target against NSCLC [138, 139] or tumors in general, and it is difficult to characterize cancer stem cells and necessary to optimize the roles and definitions of specific exosomes for each type of cancer. Such research would be a milestone in developing new therapies and new approaches to screening oncologic patients.
Author details

Beatrice Aramini\textsuperscript{1*}, Valentina Masciale\textsuperscript{1}, Federico Banchelli\textsuperscript{2}, Roberto D’Amico\textsuperscript{2}, Massimo Dominici\textsuperscript{3} and Khawaja Husnain Haider\textsuperscript{4}

1 Division of Thoracic Surgery, University of Modena and Reggio Emilia, Modena, Italy
2 Center of Statistic, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
3 Division of Oncology, Department of Medical and Surgical Sciences, University of Modena and Reggio Emilia, Modena, Italy
4 Department of Basic Sciences, Sulaiman AlRajhi Medical School, Sulaiman Alrajhi University, Kingdom of Saudi Arabia

*Address all correspondence to: beatrice.aramini@unimore.it

© 2020 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
References


[94] von Laffert M, Schirmacher P, Warth A, Büttner R, Huber RM et al. (2017) ALK-testing in non-small cell lung cancer (NSCLC): immunohistochemistry (IHC) and/or fluorescence in-situ hybridisation (FISH)?: statement of the Germany Society for Pathology (DGP) and the Working Group Thoracic Oncology (AIO) of the German Cancer Society e.V. (Stellungnahme der Deutschen Gesellschaft für Pathologie und der AG Thorakale Onkologie der...


